vs
Side-by-side financial comparison of CSP INC (CSPI) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $12.0M, roughly 1.0× CSP INC). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 0.8%, a 249.9% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -23.2%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -6.3%).
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
CSPI vs SPRO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $12.6M |
| Net Profit | $91.0K | $31.5M |
| Gross Margin | 39.3% | — |
| Operating Margin | -0.9% | — |
| Net Margin | 0.8% | 250.7% |
| Revenue YoY | -23.2% | 24080.8% |
| Net Profit YoY | -80.7% | 250.9% |
| EPS (diluted) | $0.01 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.0M | $12.6M | ||
| Q3 25 | $14.5M | $0 | ||
| Q2 25 | $15.4M | $0 | ||
| Q1 25 | $13.1M | $12.0K | ||
| Q4 24 | $15.7M | $52.0K | ||
| Q3 24 | $13.0M | $65.0K | ||
| Q2 24 | $13.1M | $114.0K | ||
| Q1 24 | $13.7M | $140.0K |
| Q4 25 | $91.0K | $31.5M | ||
| Q3 25 | $-191.0K | $-7.4M | ||
| Q2 25 | $-264.0K | $-1.7M | ||
| Q1 25 | $-108.0K | $-13.9M | ||
| Q4 24 | $472.0K | — | ||
| Q3 24 | $-1.7M | $-17.1M | ||
| Q2 24 | $-185.0K | $-17.9M | ||
| Q1 24 | $1.6M | $-12.7M |
| Q4 25 | 39.3% | — | ||
| Q3 25 | 36.6% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.0% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 28.4% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 47.3% | — |
| Q4 25 | -0.9% | — | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | -7.9% | — | ||
| Q1 25 | -7.6% | -122758.3% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -15.7% | -28604.6% | ||
| Q2 24 | -5.5% | -16720.2% | ||
| Q1 24 | 9.0% | -9987.1% |
| Q4 25 | 0.8% | 250.7% | ||
| Q3 25 | -1.3% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -0.8% | -115550.0% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -12.7% | -26380.0% | ||
| Q2 24 | -1.4% | -15668.4% | ||
| Q1 24 | 11.6% | -9049.3% |
| Q4 25 | $0.01 | $0.56 | ||
| Q3 25 | $-0.02 | $-0.13 | ||
| Q2 25 | $-0.03 | $-0.03 | ||
| Q1 25 | $-0.01 | $-0.25 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.17 | $-0.32 | ||
| Q2 24 | $-0.02 | $-0.33 | ||
| Q1 24 | $0.16 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8M | $59.0M |
| Total Assets | $69.2M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $40.3M | ||
| Q3 25 | $27.4M | $48.6M | ||
| Q2 25 | $26.3M | $31.2M | ||
| Q1 25 | $29.5M | $48.9M | ||
| Q4 24 | $30.7M | $52.9M | ||
| Q3 24 | $30.6M | $76.3M | ||
| Q2 24 | $28.9M | $63.5M | ||
| Q1 24 | $27.1M | $82.3M |
| Q4 25 | $44.8M | $59.0M | ||
| Q3 25 | $44.6M | $26.5M | ||
| Q2 25 | $47.5M | $32.8M | ||
| Q1 25 | $47.5M | $33.8M | ||
| Q4 24 | $47.5M | $46.1M | ||
| Q3 24 | $47.3M | $65.5M | ||
| Q2 24 | $48.1M | $80.5M | ||
| Q1 24 | $48.2M | $96.2M |
| Q4 25 | $69.2M | $68.9M | ||
| Q3 25 | $71.2M | $54.2M | ||
| Q2 25 | $66.8M | $62.1M | ||
| Q1 25 | $67.1M | $77.7M | ||
| Q4 24 | $67.5M | $110.5M | ||
| Q3 24 | $69.4M | $135.2M | ||
| Q2 24 | $66.8M | $149.9M | ||
| Q1 24 | $64.2M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-8.4M |
| Free Cash FlowOCF − Capex | $-3.0M | — |
| FCF MarginFCF / Revenue | -25.1% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | -32.04× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $-8.4M | ||
| Q3 25 | $1.9M | $17.4M | ||
| Q2 25 | $-3.3M | $-17.7M | ||
| Q1 25 | $1.9M | $-4.0M | ||
| Q4 24 | $1.7M | $-23.4M | ||
| Q3 24 | $-1.5M | $12.8M | ||
| Q2 24 | $2.4M | $-18.7M | ||
| Q1 24 | $1.7M | $5.9M |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-1.5M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $1.6M | — |
| Q4 25 | -25.1% | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | -21.7% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | -11.7% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | -32.04× | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
SPRO
Segment breakdown not available.
